JOUNCE THERAPEUTICS

jounce-therapeutics-logo

Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is discovering and developing first-in-class cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce’s proprietary product engine is driving this transformational approach, which has the potential to drive significantly more durable responses to treatment, extending and improving patients’ quality of life. Founded by world leaders in immunobiology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures.

#SimilarOrganizations #People #Financial #Website #More

JOUNCE THERAPEUTICS

Social Links:

Industry:
Biotechnology Pharmaceutical Therapeutics

Founded:
2013-01-01

Address:
Cambridge, Massachusetts, United States

Country:
United States

Website Url:
http://www.jouncetx.com

Total Employee:
101+

Status:
Active

Contact:
617-585-2000

Total Funding:
194.25 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics Font Awesome Domain Not Resolving Global Site Tag


Similar Organizations

rome-therapeutics-logo

ROME Therapeutics

ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.

rani-therapeutics-logo

Rani Therapeutics

Rani Therapeutics develops bio-therapeutics technology for the oral delivery of large drug molecules.

resolve-therapeutics-logo

Resolve Therapeutics

Resolve Therapeutics is focused on developing a novel approach to the treatment of Systemic Lupus Erythematosus (SLE).

rodeo-therapeutics-logo

Rodeo Therapeutics

Rodeo Therapeutics is a developer of small-molecule therapies designed to promote regeneration and repair of multiple tissue types.

resonant-therapeutics-logo

Resonant Therapeutics

Resonant Therapeutics is a scalable tumor microenvironment platform that speeds up therapeutic & goal discovery.

rigel-pharmaceuticals-logo

Rigel Pharmaceuticals

Rigel Pharmaceuticals develops small-molecule drugs for the treatment of autoimmune diseases, cancer and metabolic diseases.

nivien-therapeutics-logo

Nivien Therapeutics

Nivien Therapeutics is developing the first small molecule drugs to enhance both chemo and immunotherapies.

nimble-therapeutics-logo

Nimble Therapeutics

Nimble Therapeutics is bringing the power of massively parallel chemical synthesis to drug discovery.

veralox-therapeutics-logo

Veralox Therapeutics

Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes.

verseon-logo

Verseon

Verseon’s breakthroughs in computational chemistry, AI, & synthesis create novel pharmaceuticals. Atom by atom, we drive innovation.

verseau-therapeutics-logo

Verseau Therapeutics

Verseau focus is building a pipeline of first-in-class therapies that modulate macrophages to trigger a coordinated immune attack on cancer.

ventus-therapeutics-logo

Ventus Therapeutics

Ventus Therapeutics develops small molecule drugs that target autoimmune diseases, inflammatory diseases, and cancer.

vasorx-logo

VasoRx

VasoRx is developing RNA therapies for diseases of the cardiovascular system & oncology such as atherosclerosis and pulmonary hypertension.

memgen-logo

Memgen

Memgen is a clinical stage biotech developing cancer immunotherapies to harness the power of the immune system to cure cancer

modus-therapeutics-logo

Modus Therapeutics

Modus Therapeutics is a Swedish drug development company focused on normalizing the lives for patients with Sickle Cell Disease.

myoscience-logo

MyoScience

MyoScience develops and commercializes technology-driven dermatological products.

lassen-therapeutics-logo

Lassen Therapeutics

Lassen Therapeutics is developing novel, best-in-class biotherapeutics to improve the lives of patients suffering from serious diseases.

aqualung-therapeutics-logo

Aqualung Therapeutics

Aqualung Therapeutics is developing a novel, anti-inflammatory monoclonal antibody strategy to treat serious unchecked inflammation.

actuate-therapeutics-logo

Actuate Therapeutics

Actuate Therapeutics provides advanced research for the treatment of high-impact cancers and neurodegenerative diseases.

apellis-pharmaceuticals-logo

Apellis Pharmaceuticals

Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.

aligos-therapeutics-logo

Aligos Therapeutics

Aligos Therapeutics is discovering and developing new classes of molecules that interact directly with disease-causing modalities.

advaxis-logo

Advaxis

Advaxis is a developer of multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer.

alcyone-therapeutics-logo

Alcyone Therapeutics

Alcyone Therapeutics is Pioneering Next-Generation Precision CNS Genetic Therapies to unlock new possibilities

apim-therapeutics-logo

APIM Therapeutics

APIM Therapeutics is developing proprietary peptide drugs targeting PCNA (Proliferating Cell Nuclear Antigen).

adagio-therapeutics-logo

Adagio Therapeutics

Adagio Therapeutics offers research and development of therapeutic pharmaceuticals related to COVID-19.

aimmune-therapeutics-logo

Aimmune Therapeutics

Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.

allena-pharmaceuticals-logo

Allena Pharmaceuticals

Allena Pharmaceuticals develops and commercializes non-systemic protein therapeutics to treat metabolic and orphan diseases.

astrocyte-pharmaceuticals-logo

Astrocyte Pharmaceuticals

Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain injury patients.

adamas-pharmaceuticals-logo

Adamas Pharmaceuticals

Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.

altor-bioscience-logo

Altor BioScience

Altor BioScience researches and develops immunotherapeutic agents for the treatment of cancer, viral infections and autoimmune diseases.

elicio-therapeutics-logo

Elicio Therapeutics

Elicio Therapeutics develops an immuno-tumor vaccine to treat cancer.

benevir-biopharm-logo

BeneVir Biopharm

Maryland startup BeneVir is developing immunotherapy viruses that rid the body of two types of tumor cells.

bioject-medical-technologies-logo

Bioject Medical Technologies

Bioject Medical Technologies develops needle-free injection therapies to improve the administration of liquid medications such as vaccines.

faraday-pharmaceuticals-logo

Faraday Pharmaceuticals

Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury.

7-hills-pharma-logo

7 Hills Pharma

7 Hills Pharma is developing novel immunotherapies for the treatment Of cancer.

txcell-logo

TxCell

TxCell develops cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases.

tyme-logo

TYME

TYME is an emerging biotech developing cancer therapeutics intended to be broadly effective across tumor types with low toxicity profiles.

tau-therapeutics-logo

Tau Therapeutics

Tau Therapeutics engages in the R&D, repositioning and commercialization of calcium T-channel therapies for oncology and other diseases.

taiga-biotechnologies-logo

Taiga Biotechnologies

Taiga Biotechnologies is a clinical-stage company focused on harnessing the immune system to fight infectious disease and cancer.

janux-therapeutics-logo

Janux Therapeutics

Janux Therapeutics develops immunotherapies that generates immune responses to prevent tumors and not affecting a patient’s healthy tissue.

annovis-bio-logo

Annovis Bio

Annovis Bio develops novel treatments for Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders.

kineta-logo

Kineta

Kineta aims at developing edge therapeutics in autoimmune disease, viral disease, and chronic pain areas.

kodikaz-therapeutic-solutions-logo

Kodikaz Therapeutic Solutions

Kodikaz is a gene therapy platform company that has the unique technical ability of specifically targeting cancer cells.

walking-fish-therapeutics-logo

Walking Fish Therapeutics

Walking Fish Therapeutics is developing a platform to harness B cells’ capability to activate the immune system.

wugen-logo

Wugen

Wugen is developing off-the-shelf cellular therapies targeting solid tumors and hematologic malignancies

stipe-therapeutics-logo

STipe Therapeutics

STipe Therapeutics focuses on harnessing the innate immune system to battle cancer.

sequoia-sciences-logo

Sequoia Sciences

Sequoia Sciences is a pharmaceutical company discovering and developing new medicines for the treatment of bacterial infections and cancers.

synthex-logo

SyntheX

SyntheX is a biotechnology company reimagining precision therapeutics with new drug discovery technologies focused on protein modulation.

dignify-therapeutics-logo

Dignify Therapeutics

Dignify Therapeutics is a drug development company focused on delivering novel drug therapies for bladder and bowel disorders in spinal.

hdt-bio-logo

HDT Bio

IMMUNE THERAPY FOR ALL: We’re transforming inventive immunotherapies for oncology and infectious disease.

heptares-therapeutics-logo

Heptares Therapeutics

Heptares Therapeutics develops novel, small-molecule drugs for G-protein-coupled receptors (GPCRs).

immune-pharmaceuticals-logo

Immune Pharmaceuticals

Immune Pharmaceuticals applies a personalized approach to treatment and developing novel antibody therapeutics.

iconic-therapeutics-logo

Iconic Therapeutics

Iconic Therapeutics develops and commercializes immunoconjugate proteins that trigger the immune system to destroy invader cells.

irx-therapeutics-logo

IRX Therapeutics

IRX Therapeutics develops immune therapies designed to activate a patient’s immune system to defeat cancer and related diseases.

imcyse-logo

Imcyse

Developing disease specific immune therapies to treat severe, chronic auto-immune, inflammatory, allergic, infectious diseases and tumors.

inmunebio-logo

INmuneBIO

INmune Bio is developing therapies that harness the patient’s immune system to treat cancer.

genedit-logo

GenEdit

GenEdit develops next generation therapeutics for genetic diseases through safe and efficient CRISPR/Cas9 delivery.

gitr-logo

GITR

GITR develops therapies to enhance the immune system by enabling T cells to be more effective in attacking cancer cells.

go-therapeutics-logo

GO Therapeutics

A new generation of cancer immunotherapy promise to change the paradigm of cancer treatment.

geneos-therapeutics-logo

Geneos Therapeutics

Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.

g-con-manufacturing-logo

G-CON Manufacturing

G-CON Manufacturing designs, produces, and installs prefabricated cleanrooms called PODs.

coferon-logo

Coferon

Coferon employs bioorthogonal linker chemistry to deliver therapeutic molecules in component parts that self assembles inside target cells.

cytunepharma-logo

CytunePharma

Cytune’s goal is to turn novel concepts into best-in class immunotherapeutics restoring and activating the immune system to fight cancer.

carmine-therapeutics-logo

Carmine Therapeutics

Carmine Therapeutics is developing novel types of gene therapies that utilize extracellular vesicles (EVs) produced in the laboratory.

chaperone-therapeutics-logo

Chaperone Therapeutics

Chaperone Therapeutics is developing frontline therapies to address diseases of protein misfolding

cyteir-therapeutics-logo

Cyteir Therapeutics

Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.

cybrexa-therapeutics-logo

Cybrexa Therapeutics

Cybrexa Therapeutics is a cancer therapeutics company developing a new class of small molecule DNA repair.

cour-pharmaceuticals-development-logo

Cour Pharmaceuticals Development

Cour Pharmaceuticals Development is developing nanoparticle technology to help reset the immune system of multiple sclerosis (MS) patients.

prelude-therapeutics-logo

Prelude Therapeutics

Prelude Therapeutics designs and develops small molecule therapies targeting key drivers of cancer cell growth and resistance.

pear-therapeutics-logo

Pear Therapeutics

Pear Therapeutics is a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals.

porton-advanced-solutions-logo

Porton Advanced Solutions

Porton Advanced Solutions provide end-to-end process development (PD), analytical development (AD), GMP manufacturing, and testing services.

prism-biolab-logo

PRISM BioLab

PRISM develop therapeutic drugs that cure these intractable diseases using our unique peptide mimic technology.

protom-international-logo

ProTom International

ProTom International is a leading device manufacturer of proton therapy technology.

pulmatrix-logo

Pulmatrix

Pulmatrix develops inhaled therapies for the treatment, prevention and transmission of infectious and progressive respiratory diseases.


Current Advisors List

luis-diaz_image

Luis Diaz Director @ Jounce Therapeutics
Board_member
2017-10-23

barbara-duncan_image

Barbara Duncan Board Member @ Jounce Therapeutics
Board_member
2016-06-01

robert-kamen_image

Robert Kamen Board of Directors @ Jounce Therapeutics
Board_member
2013-01-01

perry-karsen_image

Perry Karsen Member of the Board of Directors @ Jounce Therapeutics
Board_member

duncan-higgons_image

Duncan Higgons Board Member @ Jounce Therapeutics
Board_member
2015-11-01

jigar-raythatha_image

Jigar Raythatha Board Member @ Jounce Therapeutics
Board_member
2021-09-01

Current Employees Featured

padmanee-sharma_image

Padmanee Sharma
Padmanee Sharma Founder @ Jounce Therapeutics
Founder

julia-keith_image

Julia Keith
Julia Keith Business Development Manager @ Jounce Therapeutics
Business Development Manager
2019-03-01

cary-pfeffer_image

Cary Pfeffer
Cary Pfeffer Interim CEO @ Jounce Therapeutics
Interim CEO

thomas-f-gajewski_image

Thomas F. Gajewski
Thomas F. Gajewski Founder @ Jounce Therapeutics
Founder

kim-drapkin_image

Kim Drapkin
Kim Drapkin CFO @ Jounce Therapeutics
CFO
2015-08-01

allison-nance_image

Allison Nance
Allison Nance Senior Vice President, Regulatory Affairs & Quality Assurance @ Jounce Therapeutics
Senior Vice President, Regulatory Affairs & Quality Assurance
2016-05-01

drew-pardoll_image

Drew Pardoll
Drew Pardoll Founder @ Jounce Therapeutics
Founder

stephen-farrand_image

Stephen Farrand
Stephen Farrand Chief Technical Officer @ Jounce Therapeutics
Chief Technical Officer
2016-09-01

robert-kamen_image

Robert Kamen
Robert Kamen Interim Chief Technology Officer @ Jounce Therapeutics
Interim Chief Technology Officer
2013-01-01

hugh-m-cole_image

Hugh M Cole
Hugh M Cole Chief Business Officer & Head of Corporate Development @ Jounce Therapeutics
Chief Business Officer & Head of Corporate Development
2017-08-01

Founder


drew-pardoll_image

Drew Pardoll

james-p-allison_image

James P. Allison

louis-m-weiner_image

Louis M. Weiner

padmanee-sharma_image

Padmanee Sharma

robert-d-schreiber_image

Robert D. Schreiber

thomas-f-gajewski_image

Thomas F. Gajewski

Stock Details


Company's stock symbol is NASDAQ:JNCE

Investors List

casdin-capital_image

Casdin Capital

Casdin Capital investment in Series B - Jounce Therapeutics

foresite-capital_image

Foresite Capital

Foresite Capital investment in Series B - Jounce Therapeutics

omega-funds_image

Omega Funds

Omega Funds investment in Series B - Jounce Therapeutics

wellington-management_image

Wellington Management

Wellington Management investment in Series B - Jounce Therapeutics

nextech-invest_image

Nextech Invest

Nextech Invest investment in Series B - Jounce Therapeutics

redmile-group_image

Redmile Group

Redmile Group investment in Series B - Jounce Therapeutics

cormorant-asset-management_image

Cormorant Asset Management

Cormorant Asset Management investment in Series B - Jounce Therapeutics

inbio-ventures_image

Inbio Ventures

Inbio Ventures investment in Series B - Jounce Therapeutics

pharmstandard_image

Pharmstandard

Pharmstandard investment in Series B - Jounce Therapeutics

third-rock-ventures_image

Third Rock Ventures

Third Rock Ventures investment in Series A - Jounce Therapeutics

Official Site Inspections

http://www.jouncetx.com Semrush global rank: 3.34 M Semrush visits lastest month: 4.78 K

  • Host name: 104.21.62.152
  • IP address: 104.21.62.152
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Jounce Therapeutics"

Jounce Therapeutics - Crunchbase Company Profile

Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is discovering and developing first-in-class cancer immunotherapies designed to harness the immune system to seek out and attack cancerous …See details»

Jounce Therapeutics Enters Into Agreement to Be Acquired by …

Mar 27, 2023 Pursuant and subject to the terms of the merger agreement, a subsidiary of Concentra will commence a tender offer by April 7, 2023 to acquire all outstanding shares of …See details»

Redx and Jounce Announce Recommended Business Combination …

Feb 23, 2023 Management and Organization. Named Redx Inc., the combined group will be solely listed on Nasdaq in the US under the ticker symbol REDX. Led by current Redx CEO …See details»

Jounce Therapeutics, Inc. Information - RocketReach

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack …See details»

Jounce Therapeutics, Inc. | LinkedIn

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and ...See details»

Redx and Jounce Announce Recommended Business Combination

Mar 3, 2023 The Business Combination will create a transatlantic organization with proven expertise in both small molecule drugs and biologics, and a clinical pipeline with multiple value …See details»

Redx and Jounce Announce Recommended Business Combination

Feb 23, 2023 Management and Organization Named Redx Inc. , the combined group will be solely listed on Nasdaq in the US under the ticker symbol REDX. Led by current Redx CEO …See details»

Jounce Therapeutics Announces Closing of Tender Offer - Yahoo …

May 4, 2023 The tender offer expired at 6:00 p.m., Eastern Time, on May 3, 2023. As of the expiration of the offer, 36,367,727 shares of Jounce common stock had been validly tendered …See details»

Jounce Therapeutics - Craft

May 5, 2023 Jounce Therapeutics is a clinical-stage immunotherapy company. It develops cancer treatment therapies. It provides the translational science platform that identifies …See details»

Gilead Sciences and Jounce Therapeutics Announce Exclusive …

Sep 1, 2020 Jounce expects JTX-8064 to enter the clinic in 2020. JTX-1811 is a monoclonal antibody targeting CCR8 which is designed to selectively deplete T regulatory cells in the …See details»

Jounce Therapeutics Enters Into Agreement to Be Acquired by

Mar 27, 2023 Jounce Therapeutics, Inc. Kim Drapkin ir@jouncetx.com: T: +1-857-259-3840 Cowen (Financial Adviser to Jounce) T: +1-646-562-1010: Tanya Joseph / Erik Schuchard / …See details»

Jounce Therapeutics Appoints Jigar Raythatha to its Board of …

CAMBRIDGE, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel …See details»

Redx & Jounce Announce Recommended Business Combination

The Business Combination will create a transatlantic organization with proven expertise in both small molecule drugs and biologics, and a clinical pipeline with multiple value inflection points …See details»

Jounce Therapeutics Progresses INNATE Study of JTX-8064

Oct 7, 2021 For more information, please visit www.jouncetx.com. Cautionary Note Regarding Forward-Looking Statements: Various statements in this release concerning Jounce’s future …See details»

Jounce Therapeutics Announces Pricing of $56.25 Million Public …

Mar 10, 2021 Investor and Media Contacts:Malin DeonJounce Therapeutics, Inc.+1-857-259-3843mdeon@jouncetx.com Mark YoreJounce Therapeutics, Inc.+1-857-200-1255 …See details»

Jounce Therapeutics Presents First Preclinical Data on Anti

Jun 22, 2020 For more information, please visit www.jouncetx.com. Cautionary Note Regarding Forward-Looking StatementsVarious statements in this release concerning Jounce’s future …See details»

Jounce Therapeutics Reports Fourth Quarter and Full Year

Mar 2, 2022 For more information, please visit www.jouncetx.com. Cautionary Note Regarding Forward-Looking Statements: Various statements in this release concerning Jounce’s future …See details»

Jounce Therapeutics | Cambridge MA - Facebook

Jounce Therapeutics, Cambridge, Massachusetts. 362 likes · 16 were here. Dedicated to Transforming the Treatment of CancerSee details»

Jounce Therapeutics Announces Results from Pre-Planned Data

Mar 16, 2023 Pimivalimab is a PD-1 inhibitor intended for combination use with Jounce’s broader pipeline. For more information, please visit www.jouncetx.com. Cautionary Note …See details»

Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical …

Dec 8, 2022 - INNATE trial Phase 1 dose escalation data showed JTX-8064 was well-tolerated as a single agent and in combination with pimivalimab (pimi) - - Patient with advanced biliary …See details»

linkstock.net © 2022. All rights reserved